PROCEPT BioRobotics Corporation (PRCT)
Automate Your Wheel Strategy on PRCT
With Tiblio's Option Bot, you can configure your own wheel strategy including PRCT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PRCT
- Rev/Share 4.5363
- Book/Share 7.0863
- PB 9.1797
- Debt/Equity 0.2051
- CurrentRatio 8.9465
- ROIC -0.2113
- MktCap 3599129788.0
- FreeCF/Share -1.6062
- PFCF -40.8037
- PE -39.6079
- Debt/Assets 0.1537
- DivYield 0
- ROE -0.2809
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
PROCEPT BioRobotics Corporation (PRCT) Q1 2025 Earnings Call Transcript
Published: April 24, 2025 by: Seeking Alpha
Sentiment: Neutral
PROCEPT BioRobotics Corporation (NASDAQ:PRCT ) Q1 2025 Earnings Conference Call April 24, 2025 8:00 AM ET Company Participants Matt Bacso - Vice President, Investor Relations & Business Operations Reza Zadno - President & Chief Executive Officer Sham Shiblaq - Executive Vice President & Chief Commercial Officer Kevin Waters - Executive Vice President & Chief Financial Officer Conference Call Participants Matthew O'Brien - Piper Sandler Craig Bijou - Bank of America Securities Patrick Wood - Morgan Stanley Richard Newitter - Truist Brandon Vazquez - William Blair Josh Jennings - TD Cowen Chris Pasquale - Nephron Research Mike Kratky - Leerink Partners …
Read More
PROCEPT BioRobotics Corporation (PRCT) Reports Q1 Loss, Tops Revenue Estimates
Published: April 24, 2025 by: Zacks Investment Research
Sentiment: Negative
PROCEPT BioRobotics Corporation (PRCT) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to loss of $0.51 per share a year ago.
Read More
WATER III Randomized-Controlled Trial Results Announced at European Association of Urology Comparing Aquablation® Therapy to Laser Enucleation
Published: March 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
Aquablation therapy delivers similar symptom score reduction, superior ejaculatory function preservation, and superior continence preservation to laser enucleation in 80–180 mL prostates in a randomized, multicenter trial Aquablation therapy delivers similar symptom score reduction, superior ejaculatory function preservation, and superior continence preservation to laser enucleation in 80–180 mL prostates in a randomized, multicenter trial
Read More
PROCEPT BioRobotics Corporation (PRCT) Reports Q4 Loss, Tops Revenue Estimates
Published: February 25, 2025 by: Zacks Investment Research
Sentiment: Neutral
PROCEPT BioRobotics Corporation (PRCT) came out with a quarterly loss of $0.35 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.54 per share a year ago.
Read More
PROCEPT BioRobotics® Reports Fourth Quarter and Full Year 2024 Results
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN JOSE, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported financial results for the fourth quarter and year ended December 31, 2024.
Read More
About PROCEPT BioRobotics Corporation (PRCT)
- IPO Date 2021-09-15
- Website https://www.procept-biorobotics.com
- Industry Medical - Devices
- CEO Dr. Reza Zadno Ph.D.
- Employees 756